167 related articles for article (PubMed ID: 31273750)
1. An adaptive trial design to optimize dose-schedule regimes with delayed outcomes.
Lin R; Thall PF; Yuan Y
Biometrics; 2020 Mar; 76(1):304-315. PubMed ID: 31273750
[TBL] [Abstract][Full Text] [Related]
2. A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes.
Lin R; Thall PF; Yuan Y
Bayesian Anal; 2021 Mar; 16(1):179-202. PubMed ID: 34267857
[TBL] [Abstract][Full Text] [Related]
3. Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes.
Thall PF; Nguyen HQ; Braun TM; Qazilbash MH
Biometrics; 2013 Sep; 69(3):673-82. PubMed ID: 23957592
[TBL] [Abstract][Full Text] [Related]
4. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
Takeda K; Morita S; Taguri M
Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
[TBL] [Abstract][Full Text] [Related]
5. Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.
Thall PF; Cook JD; Estey EH
J Biopharm Stat; 2006; 16(5):623-38. PubMed ID: 17037262
[TBL] [Abstract][Full Text] [Related]
6. Effective sample size for computing prior hyperparameters in Bayesian phase I-II dose-finding.
Thall PF; Herrick RC; Nguyen HQ; Venier JJ; Norris JC
Clin Trials; 2014 Dec; 11(6):657-66. PubMed ID: 25179541
[TBL] [Abstract][Full Text] [Related]
7. Improved adaptive randomization strategies for a seamless Phase I/II dose-finding design.
Yan D; Wages NA; Dressler EV
J Biopharm Stat; 2019; 29(2):333-347. PubMed ID: 30451068
[TBL] [Abstract][Full Text] [Related]
8. Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups.
Lee J; Thall PF; Msaouel P
Stat Med; 2021 Oct; 40(24):5199-5217. PubMed ID: 34636054
[TBL] [Abstract][Full Text] [Related]
9. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
Yin G; Li Y; Ji Y
Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
[TBL] [Abstract][Full Text] [Related]
10. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
Koopmeiners JS; Modiano J
Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
[TBL] [Abstract][Full Text] [Related]
11. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies.
Zhou Y; Lee JJ; Yuan Y
Stat Med; 2019 Dec; 38(28):5299-5316. PubMed ID: 31621952
[TBL] [Abstract][Full Text] [Related]
12. Bayesian cancer clinical trial designs with subgroup-specific decisions.
Thall PF
Contemp Clin Trials; 2020 Mar; 90():105860. PubMed ID: 31678411
[TBL] [Abstract][Full Text] [Related]
13. Dose-finding based on efficacy-toxicity trade-offs.
Thall PF; Cook JD
Biometrics; 2004 Sep; 60(3):684-93. PubMed ID: 15339291
[TBL] [Abstract][Full Text] [Related]
14. Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.
Yada S; Hamada C
Pharm Stat; 2017 Mar; 16(2):114-121. PubMed ID: 27892650
[TBL] [Abstract][Full Text] [Related]
15. Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials.
Houede N; Thall PF; Nguyen H; Paoletti X; Kramar A
Biometrics; 2010 Jun; 66(2):532-40. PubMed ID: 19673865
[TBL] [Abstract][Full Text] [Related]
16. A Bayesian dose-finding design for phase I/II clinical trials with nonignorable dropouts.
Guo B; Yuan Y
Stat Med; 2015 May; 34(10):1721-32. PubMed ID: 25626676
[TBL] [Abstract][Full Text] [Related]
17. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
Xie F; Ji Y; Tremmel L
Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
[TBL] [Abstract][Full Text] [Related]
18. A Bayesian phase I-II clinical trial design to find the biological optimal dose on drug combination.
Wang Z; Zhang J; Xia T; He R; Yan F
J Biopharm Stat; 2024 Jul; 34(4):582-595. PubMed ID: 37461311
[TBL] [Abstract][Full Text] [Related]
19. Quantification of prior impact in terms of effective current sample size.
Wiesenfarth M; Calderazzo S
Biometrics; 2020 Mar; 76(1):326-336. PubMed ID: 31364156
[TBL] [Abstract][Full Text] [Related]
20. Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials.
Shimamura F; Hamada C; Matsui S; Hirakawa A
J Biopharm Stat; 2018; 28(6):1025-1037. PubMed ID: 29420127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
